{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:39:44Z","timestamp":1762987184229,"version":"3.45.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,28]],"date-time":"2021-01-28T00:00:00Z","timestamp":1611792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jtocrr.2021.100155","type":"journal-article","created":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T01:42:04Z","timestamp":1613439724000},"page":"100155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma"],"prefix":"10.1016","volume":"2","author":[{"given":"Robert A.","family":"Belderbos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander P.W.M.","family":"Maat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara J.","family":"Baart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva V.E","family":"Madsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ad J.J.C.","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edris A.F.","family":"Mahtab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H.","family":"von der Th\u00fcsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2021.100155_bib1","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1183\/09031936.00000811","article-title":"Predicting survival in malignant mesothelioma","volume":"38","author":"Musk","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtocrr.2021.100155_bib2","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib3","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial [published correction appears in Lancet. 2016;387:e24]","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"issue":"suppl","key":"10.1016\/j.jtocrr.2021.100155_bib4","article-title":"2908 first-line nivolumab\u00a0+ ipilimumab vs chemotherapy in unresectable malignant pleural mesothelioma: CheckMate 743","volume":"15","author":"Baas","year":"2020","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib5","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib6","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.jtho.2018.08.001","article-title":"Surgery in malignant pleural mesothelioma","volume":"13","author":"Bueno","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtocrr.2021.100155_bib9","first-page":"10","article-title":"Extended pleurectomy decortication for the treatment of malignant pleural mesothelioma","volume":"2019","author":"Maat","year":"2019","journal-title":"Multimed Man Cardiothorac Surg"},{"key":"10.1016\/j.jtocrr.2021.100155_bib10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2013.11.026","article-title":"A\u00a0systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma","volume":"83","author":"Cao","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2021.100155_bib11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/JTO.0000000000000064","article-title":"Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of\u00a01365 consecutive patients","volume":"9","author":"Bovolato","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib12","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1097\/JTO.0b013e31818b174d","article-title":"Treatment of malignant pleural mesothelioma with carboplatin, liposomized doxorubicin, and gemcitabine: a phase II study","volume":"3","author":"Hillerdal","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib13","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1186\/s12885-018-5064-4","article-title":"Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma","volume":"18","author":"Schwartz","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jtocrr.2021.100155_bib14","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.21037\/jtd.2016.07.55","article-title":"Validation of EORTC and CALGB prognostic models in surgical patients submitted to diagnostic, palliative or curative surgery for malignant pleural mesothelioma","volume":"8","author":"Sandri","year":"2016","journal-title":"J\u00a0Thorac Dis"},{"key":"10.1016\/j.jtocrr.2021.100155_bib15","first-page":"402","article-title":"Mesothelioma: scientific clues for prevention, diagnosis, and therapy [published correction appears in CA Cancer J\u00a0Clin. 2020;70:313\u2013314]","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jtocrr.2021.100155_bib16","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","article-title":"Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials","volume":"23","author":"Fennell","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","article-title":"Inflammation-based prognostic indices in malignant pleural mesothelioma","volume":"7","author":"Pinato","year":"2012","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib18","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/JTO.0000000000000055","article-title":"PI3K\/mTOR signaling in mesothelioma patients treated with induction chemotherapy followed by extrapleural pneumonectomy","volume":"9","author":"Bitanihirwe","year":"2014","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib20","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1136\/jcp.2010.076794","article-title":"FISH assay development for the detection of p16\/CDKN2A deletion in malignant pleural mesothelioma","volume":"63","author":"Chung","year":"2010","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.jtocrr.2021.100155_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bjc.2015.9","article-title":"Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study","volume":"112","author":"Ghanim","year":"2015","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2021.100155_bib23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/modpathol.2011.146","article-title":"A\u00a0nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma","volume":"25","author":"Kadota","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib24","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/COC.0b013e3182a0e867","article-title":"Prognostic significance of Ki67 expression in malignant peritoneal mesothelioma","volume":"38","author":"Pillai","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib26","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/modpathol.2017.170","article-title":"Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study","volume":"31","author":"Rosen","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/PAI.0b013e3181dddb20","article-title":"Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study","volume":"18","author":"Nassar","year":"2010","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib28","doi-asserted-by":"crossref","first-page":"57460","DOI":"10.18632\/oncotarget.15404","article-title":"Prognostic significance of neutrophil-to-lymphocyte ratio in patients with malignant pleural mesothelioma: a meta-analysis","volume":"8","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtocrr.2021.100155_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186852","article-title":"Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort","volume":"12","author":"Richardsen","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2021.100155_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in breast cancer: prognostic and predictive potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jtcvs.2018.10.039","article-title":"Treatment of malignant pleural mesothelioma with chemotherapy preceding versus after surgical resection","volume":"157","author":"Verma","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtocrr.2021.100155_bib32","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1245\/s10434-015-4962-9","article-title":"The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)","volume":"23","author":"Kusamura","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib33","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2016.10.11","article-title":"What is better\/reliable, mitosis counting or Ki67\/MIB1 staining?","volume":"5","author":"Kriegsmann","year":"2016","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100155_bib34","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas","year":"2010","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib35","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1200\/JCO.2017.76.6394","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Kindler","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib36","doi-asserted-by":"crossref","first-page":"543","DOI":"10.21037\/tlcr.2018.07.05","article-title":"The eighth TNM classification for malignant pleural mesothelioma","volume":"7","author":"Berzenji","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.jtocrr.2021.100155_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145039","article-title":"Determinants of survival in malignant pleural mesothelioma: a surveillance, epidemiology, and end results (SEER) study of 14,228 patients","volume":"10","author":"Taioli","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jtocrr.2021.100155_bib38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.athoracsur.2017.09.036","article-title":"National trends in the epidemiology of malignant pleural mesothelioma: a national cancer data base study","volume":"105","author":"Saddoughi","year":"2018","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtocrr.2021.100155_bib39","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jtho.2015.12.108","article-title":"A\u00a0novel clinical prediction model for prognosis in malignant pleural mesothelioma using decision tree analysis","volume":"11","author":"Brims","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2021.100155_bib40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.113.3.723","article-title":"Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B","volume":"113","author":"Herndon","year":"1998","journal-title":"Chest"},{"key":"10.1016\/j.jtocrr.2021.100155_bib41","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1159\/000321370","article-title":"A\u00a0clinical, radiographic and laboratory evaluation of prognostic factors in 363 patients with malignant pleural mesothelioma","volume":"80","author":"Tanrikulu","year":"2010","journal-title":"Respiration"},{"key":"10.1016\/j.jtocrr.2021.100155_bib42","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/j.ejca.2009.04.028","article-title":"A\u00a0prognostic index for progression-free survival in malignant mesothelioma with application to the design of phase II trials: a combined analysis of 10 EORTC trials","volume":"45","author":"Francart","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtocrr.2021.100155_bib43","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1010-7940(02)00721-2","article-title":"Validation of the Charlson comorbidity index in patients with operated primary non-small cell lung cancer","volume":"23","author":"Birim","year":"2003","journal-title":"Eur J Cardiothorac Surg"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432100014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266636432100014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T22:36:06Z","timestamp":1762986966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266636432100014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S266636432100014X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100155","relation":{},"ISSN":["2666-3643"],"issn-type":[{"type":"print","value":"2666-3643"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ki67 (MIB-1) as a Prognostic Marker for Clinical Decision Making Before Extended Pleurectomy Decortication in Malignant Pleural Mesothelioma","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2021.100155","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100155"}}